A Post Marketing Safety Study of Sitagliptin (JANUVIA®) (MK-0431-234)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Sitagliptin (JANUVIA®)

Study type: Observational

Funder types: Industry

Identifiers

NCT01354990

0431-234

Details and patient eligibility

About

The primary objective of this study is to obtain safety information on the use of sitagliptin (JANUVIA®) from endocrinologists, diabetologists, internists, and general practitioners.

Enrollment: 2,974 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Must be taking sitagliptin (JANUVIA™) for the treatment of type 2 diabetes

mellitus

• Treating physician must agree to provide information regarding the participants treatment

Trial design

2,974 participants in 1 patient group

Participants treated with sitagliptin

Treatment:

Drug: Sitagliptin (JANUVIA®)